BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Staging
9 results:

  • 1. Ultra high b-value diffusion weighted imaging enables better molecular grading stratification over histological grading in adult-type diffuse glioma.
    Guo J; Fu X; Li Y; Ming H; Lin Y; Yu S; Wei H; Sun C; Zhang K; Yang X
    Eur J Radiol; 2023 Nov; 168():111140. PubMed ID: 37832200
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.
    García-Lezama M; Carrillo-Ruiz JD; Moreno-Jiménez S; Roldán-Valadez E
    Gac Med Mex; 2023; 159(2):161-168. PubMed ID: 37094238
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS tumor Classification.
    Zakharova G; Efimov V; Raevskiy M; Rumiantsev P; Gudkov A; Belogurova-Ovchinnikova O; Sorokin M; Buzdin A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613601
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system.
    Soldatelli JS; Oliveira IM; Kneubil MC; Henriques JAP
    An Acad Bras Cienc; 2022; 94(3):e20211075. PubMed ID: 35766600
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.
    Mancini L; Casagranda S; Gautier G; Peter P; Lopez B; Thorne L; McEvoy A; Miserocchi A; Samandouras G; Kitchen N; Brandner S; De Vita E; Torrealdea F; Rega M; Schmitt B; Liebig P; Sanverdi E; Golay X; Bisdas S
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2377-2391. PubMed ID: 35029738
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status.
    Sudre CH; Panovska-Griffiths J; Sanverdi E; Brandner S; Katsaros VK; Stranjalis G; Pizzini FB; Ghimenton C; Surlan-Popovic K; Avsenik J; Spampinato MV; Nigro M; Chatterjee AR; Attye A; Grand S; Krainik A; Anzalone N; Conte GM; Romeo V; Ugga L; Elefante A; Ciceri EF; Guadagno E; Kapsalaki E; Roettger D; Gonzalez J; Boutelier T; Cardoso MJ; Bisdas S
    BMC Med Inform Decis Mak; 2020 Jul; 20(1):149. PubMed ID: 32631306
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Immunotherapy in gliomas: Are we reckoning without the innate immunity?
    Vismara MFM; Donato A; Malara N; Presta I; Donato G
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843378. PubMed ID: 30968718
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.
    Holdhoff M
    J Natl Compr Canc Netw; 2018 May; 16(5S):642-645. PubMed ID: 29784746
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and idh-mutation status prediction: a preliminary study.
    Bisdas S; Shen H; Thust S; Katsaros V; Stranjalis G; Boskos C; Brandner S; Zhang J
    Sci Rep; 2018 Apr; 8(1):6108. PubMed ID: 29666413
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.